MET and lung adenocarcinoma: Bean et al. have also shown that MET amplification occurs in human lung adenocarcinomas independently of T790M with resistance to gefitinib or erlotinib, emphasizing the relevant therapeutic target of MET for patients with acquired resistance to EGFR kinase inhibitors.